Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIH Drug Repurposing Program Produces Surprise Overlaps

Executive Summary

Crowdsourcing among researchers produces several applications proposing to test a few compounds in the NCATS repurposing library for use in multiple new indications, which officials did not expect.

Advertisement

Related Content

NIH Translational Science Center Gets Expanded Powers In Cures Bill
Clinical Trial Data Release: Be Careful What You Wish For, Industry Exec Says
NCATS May Consider Requesting “Active” Compounds For Repurposing Program
AstraZeneca Has Stake In Three Of Nine NCATS Research Projects
NIH Royalties For Pfizer, AstraZeneca, Lilly Drugs Remain Open Question In Repurposing Initiative
Lilly In Collaboration To Screen NIH Pharmaceuticals Collection, Make Pharmacology Data Public

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054867

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel